Indian pharma firm Zydus Cadila (NSE: CADILAHC) has been granted approval from the US Food and Drug Administration (FDA) to market Clobetasol Propionate ointment USP, 0.05%, in the US market, the company said on Monday.
Clobetasol Propionate ointment is used in the treatment of a range of skin conditions, such as eczema, dermatitis, allergies and rashes.
The company confirmed that the ointment will be manufactured at its Ahmedabad-based facility.
It marks the latest in the Zydus group's extensive portfolio of more than 165 product approvals.
Elanco Animal Health's Befrena (tirnovetmab) receives USDA approval for canine dermatitis
Blacksmith Medicines granted European patent for LpxC-targeting antibacterial compounds
AstraZeneca wins US FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps
ALK partners with GenSci to expand allergy immunotherapy market in China
Ionis publishes positive Phase 3 data supporting donidalorsen as HAE prophylactic
Blacksmith Medicines granted US patent for antibacterial compounds targeting LpxC
Alvotech reports positive topline results for Xolair biosimilar study
DBV Technologies secures up to USD306.9m to advance Viaskin peanut patch programme
Kenox Pharmaceuticals partners with Lactiga US
Health Canada approves ALK's ACARIZAX for young children with dust mite allergy
Allergy Therapeutics publishes positive Phase III data for Grass MATA MPL
CSL's ANDEMBRY receives European approval to prevent attacks of hereditary angioedema
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS